You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Harvard Business School
AstraZeneca
Johnson and Johnson

Last Updated: March 28, 2020

DrugPatentWatch Database Preview

Litigation Details for KING PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. )


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in KING PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC.
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for KING PHARMACEUTICALS, INC. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. )

Date Filed Document No. Description Snippet Link To Document
2007-08-03 103 or more claims of United States Patent No. 4,626,538 (“the 538 Patent”). This Court has jurisdiction …347 Patent”) and 4,521,422 (“the 422 Patent”) and required common ownership of the three patents.4 The…granted; (6) the 538 Patent is invalid for double patenting; (7) the 538 Patent is unenforceable due… This is an action for patent infringement of the 538 Patent,3 under which King has the right…date of the 538 Patent to coincide with the expiration date of United States Patent Nos. 4,654,347 ( External link to document
2006-01-20 27 or more claims of United States Patent No. 4,626,538 (“the ‘538 Patent”), owned by Wyeth, under which …in an earlier patent, U.S. Patent No. 4,521,422 (“the ‘422 Patent”), and the ‘538 Patent was granted only…obviousness-type double patenting rejection of a patent application may be cured by the patent applicant by filing… This is a patent infringement action commenced by King against Teva under the ‘538 Patent.2 Wyeth is…understands the history of the ‘538 Patent to be as follows. The ‘538 Patent was issued on December 2, 1986 External link to document
2007-01-22 71 or more claims of United States Patent No. 4,626,538 (“the 538 Patent”). This Court has jurisdiction … (“the 347 Patent”) and 4,521,422 (“the 422 Patent”). The 347 and 422 Patents expired on June 23, 2003… the § 156 Patent Term Extension, the 538 Patent will expire on June 6, 2008. The Patent Term Extension… that the 538 Patent expired on June 12, 2003, and thus no valid and enforceable patent is being asserted…BACKGROUND This is an action for patent infringement of the 538 Patent,2 under which King has the right External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Harvard Business School
Dow
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.